Molecular Imaging of VWF (von Willebrand Factor) and Platelet Adhesion in Postischemic Impaired Microvascular Reflow

Background: Complete mechanistic understanding of impaired microvascular reflow after myocardial infarction will likely lead to new therapies for reducing infarct size. Myocardial contrast echocardiography perfusion imaging and molecular imaging were used to evaluate the contribution of microvascular endothelial-associated VWF (von Willebrand factor) and platelet adhesion to microvascular no-reflow. Methods and Results: Myocardial infarction was produced by transient LAD ligation in WT (wild type) mice, WT mice treated with the VWF proteolytic enzyme ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), and ADAMTS13-deficient (ADAMTS13−/−) mice. Myocardial contrast echocardiography perfusion imaging and molecular imaging of VWF and platelet GP (glycoprotein) Ib&agr; were performed 30 minutes after ischemia-reperfusion. Infarct size was measured at 3 days. Mortality during ischemia-reperfusion incrementally increased in WT+ADAMTS13, WT, and ADAMTS13−/− mice (14%, 43%, and 63%, respectively; P<0.05). For WT mice, molecular imaging signal for platelets and VWF in the postischemic risk area was 4- to 5-fold higher (P<0.05) compared with both the remote nonischemic regions or to sham-treated mice. Signal enhancement in the risk area was completely abolished by ADAMTS13 treatment for both platelets (12.8±3.3 versus −1.0±4.4 IU; P<0.05) and VWF (13.9±4.0 versus −1.0±3.0 IU; P<0.05). ADAMTS13−/− compared with WT mice had 2- to 3-fold higher risk area signal for platelets (33.1±8.5 IU) and VWF (30.9±1.9 IU). Microvascular reflow in the risk area incrementally decreased for WT+ADAMTS13, WT, and ADAMTS13−/− mice (P<0.05), whereas infarct size incrementally increased (P<0.05). Conclusions: Mechanistic information on microvascular no-reflow is possible by combining perfusion and molecular imaging. In reperfused myocardial infarction, excess endothelial-associated VWF and secondary platelet adhesion in the risk area microcirculation contribute to impaired reflow and are modifiable.

[1]  A. Sinusas.  Noninvasive Evaluation of No-Reflow Phenomenon: Potential Role of Molecular Imaging , 2018, Circulation. Cardiovascular imaging.

[2]  P. Knöbl,et al.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. , 2017, Blood.

[3]  Rachel V. Stankowski,et al.  Management of No-Reflow Phenomenon in the Catheterization Laboratory. , 2017, JACC. Cardiovascular interventions.

[4]  J. Lindner,et al.  Echocardiographic Ischemic Memory Imaging Through Complement-Mediated Vascular Adhesion of Phosphatidylserine-Containing Microbubbles. , 2016, JACC. Cardiovascular imaging.

[5]  G. Niccoli,et al.  Coronary microvascular obstruction in acute myocardial infarction. , 2016, European heart journal.

[6]  O. Kamp,et al.  The role of ADAMTS13 in acute myocardial infarction: cause or consequence? , 2016, Cardiovascular research.

[7]  J. Faber,et al.  De-novo collateral formation following acute myocardial infarction: Dependence on CCR2⁺ bone marrow cells. , 2015, Journal of molecular and cellular cardiology.

[8]  Ying Zheng,et al.  Flow-driven assembly of VWF fibres and webs in in vitro microvessels , 2015, Nature Communications.

[9]  J. Lindner,et al.  Molecular Imaging of Platelet–Endothelial Interactions and Endothelial von Willebrand Factor in Early and Mid-Stage Atherosclerosis , 2015, Circulation. Cardiovascular imaging.

[10]  Junmei Chen,et al.  Hypochlorous Acid Generated by Neutrophils Inactivates ADAMTS13 , 2014, The Journal of Biological Chemistry.

[11]  F. Crea,et al.  Persistent enhanced platelet activation in patients with acute myocardial infarction and coronary microvascular obstruction: clinical implications , 2013, Thrombosis and Haemostasis.

[12]  O. McCarty,et al.  Molecular Imaging of Inflammation and Platelet Adhesion in Advanced Atherosclerosis Effects of Antioxidant Therapy With NADPH Oxidase Inhibition , 2013, Circulation. Cardiovascular imaging.

[13]  A. Chauhan,et al.  ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. , 2012, Blood.

[14]  D. Wagner,et al.  Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. , 2012, Blood.

[15]  J. Lindner,et al.  Dysregulated Selectin Expression and Monocyte Recruitment During Ischemia-Related Vascular Remodeling in Diabetes Mellitus , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[16]  O. McCarty,et al.  Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype. , 2010, JACC. Cardiovascular imaging.

[17]  R. Jaffe,et al.  Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. , 2010, JACC. Cardiovascular interventions.

[18]  Junmei Chen,et al.  Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. , 2010, Blood.

[19]  K. Kaikita,et al.  Reduced von Willebrand factor‐cleaving protease (ADAMTS13) activity in acute myocardial infarction , 2006, Journal of thrombosis and haemostasis : JTH.

[20]  R. Kloner,et al.  The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion , 2006, Basic Research in Cardiology.

[21]  M. Gawaz.  Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. , 2004, Cardiovascular research.

[22]  Z. Ruggeri,et al.  Von Willebrand factor, platelets and endothelial cell interactions , 2003, Journal of thrombosis and haemostasis : JTH.

[23]  Kazuo Fujikawa,et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. , 2002, Blood.

[24]  E. Unger,et al.  Targeted-Microbubble Binding Selectively to GPIIb IIIa Receptors of Platelet Thrombi , 2002, Investigative radiology.

[25]  K. Ley,et al.  Ultrasound Assessment of Inflammation and Renal Tissue Injury With Microbubbles Targeted to P-Selectin , 2001, Circulation.

[26]  G Baumgarten,et al.  A chronic mouse model of myocardial ischemia-reperfusion: essential in cytokine studies. , 2000, American journal of physiology. Heart and circulatory physiology.

[27]  A R Jayaweera,et al.  Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. , 1998, Circulation.

[28]  J. Harlan,et al.  Adhesion of Activated Platelets to Endothelial Cells: Evidence for a GPIIbIIIa-dependent Bridging Mechanism and Novel Roles for Endothelial Intercellular Adhesion Molecule 1 (ICAM-1), αvβ3 Integrin, and GPIbα , 1998, The Journal of experimental medicine.

[29]  G. Schmid-Schönbein,et al.  Mechanisms and consequences of cell activation in the microcirculation. , 1996, Cardiovascular research.

[30]  Y. Taniyama,et al.  Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. , 1996, Circulation.

[31]  M. Hori,et al.  Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. , 1996, Circulation.